All the latest about our company
Fecal Aβ and Tau aggregates reveal a peripheral dimension of Alzheimer’s disease proteinopathy
October 1, 2026A recent collaborative study investigated whether disease-associated amyloid-β (Aβ) and tau aggregates can be detected in human stool and ...
attyloid becomes an Alamar Certified Service Provider for NULISA™
September 14, 2026attyloid has been certified by Alamar Biosciences as an official Certified Service Provider (CSP) for NULISA™ assays on the ...
attyloid at AAIC 2026 in London: Enhancing CNS biomarker strategies
July 10, 2026How can biomarkers provide a more complete picture of neurodegenerative disease? We are excited to announce that attyloid will ...
New Publication: Exploring the Potential and Limitations of Seeded Amplification for AD and PD Biomarkers
July 10, 2026We are pleased to share our latest research paper, “Analysis of Single Particles of Amyloid Beta and α-Synuclein with ...
attyloid to showcase biomarkers across pathology and biology at AD/PD™ 2026 conference
March 3, 2026Aβ Oligomers in Focus: Clinical Advancement of PRI-002 in Nature Communications
May 6, 2025Just recently, Kutzsche et al. published major findings from a Phase 1b clinical trial evaluating the safety, tolerability, and pharmacokinetics ...
New Publication: Blood-Based Detection of Aβ Oligomers Reveals Impaired Clearance in Alzheimer’s Disease
December 17, 2024We are proud to share that our latest study featuring attyloid’s sFIDA technology has been published in Nature Communications Medicine. ...
attyloid’s sFIDA technology unveils potential non-invasive biomarker for Alzheimer’s Disease
November 4, 2024We are excited to announce a groundbreaking discovery at attyloid, made possible through our proprietary sFIDA technology, with the potential ...
Novel study highlights role of IAPP oligomerisation in type 2 diabetes progression
August 23, 2024attyloid is thrilled to share exciting findings from a recent study that explored the role of Islet amyloid polypeptide (IAPP) ...